Replies to post #405406 on Anavex Life Sciences Corp (AVXL)

[Hoskuld]

The trial was a massive success. You are responding to someone who claims to be a shareholder but has spent months trying to convince us the company lied about results.

[georgejjl]

Precision Therapeutics

Every person is unique. As a result, we aspire to develop therapeutic treatments that are tailored to suit each individual’s unique medical condition.

https://www.anavex.com/about-us

Good luck and GOD bless,

[georgejjl]

When activated by SIGMAR1 agonists, like ANAVEX®2-73, SIGMAR1 reduces cellular stress before and after RNA gene transcription. Studies confirm the predictive biomarker of response established through SIGMAR1 mRNA expression.


Because of its role in maintaining neuronal homeostasis, sigma receptors show significant promise as viable targets for therapeutic molecules in an effort to address a variety of CNS conditions.

https://www.anavex.com/sigmaceptor-explained

Good luck and GOD bless,

[georgejjl]

GOD bless,

[Anshu2]

CEO may or may not have picked the endpoint measures post-data, but that’s the impression he has given to the world (anyone sensible). (FACT: CEO never before 12/1/22 disclosed the endpoint measures and the thresholds used).

But, IRRESPECTIVE of the above, the endpoints chosen (odds-ratios) are never-used-before and meaningless (esp without n, and without dosage-wise) from an approval point of view.

There are a myriad of other problems. (1) Numerous inaccuracies/mistakes in data analysis, (2) Likely incorrect (one-tailed, Ie 1/2 of actual) p-values published, (3) No analysis per dosage arm, and finally and most importantly (4) ZERO clarification to these issues even after 9 months post-completion of trial.

Make your own judgements. Above are almost-facts, perhaps some of them are tainted by my assessments.

My summary assessment of P2b/3 is:

The trial failed.
CEO decided to hide it.
CEO has accepted it to be a P2, thus zero urgency for any updates/FDA-meetings/filings.

Once we accept the above, everything else will make sense (including, pps).

[BIOChecker4]

Read this, FWIW. https://ajtrev.substack.com/p/how-to-spin-a-trial?utm_source=substack&utm_medium=email

[Joseph_K]

Well, the Editor-in- Chief of the Journal of Alzheimer's Disease seems on board. There's a YouTube with Professor Grimmer (who's written about one million articles on Alzheimer's) about the trial (with the man who has the Anavex-informative website SOTC Analytics). Outside of AD, it's clear the scientists at the Michael J. Fox Foundation and at Cure Parkinson's think highly of blarcamesine. And read the post about Randi Hagerman's take on the efficacy of blarcamesine for Rett Syndrome patients that's at the top of this board's message list; google her, she's impressive.

Missling also hired recently the top (or among the top, I don't really know) CNS- disease biostatisticians from the FDA, who had to have a good idea of what our trials show, I would think.

You may need to wait for the peer-reviewed paper to be satisfied. My personal guess is that you will be. I'm betting on it, literally. :)